Pathway Summary for DNMT1

Overview

DNMT1 is the predominant mammalian maintenance DNA methyltransferase responsible for preserving CpG methylation patterns during DNA replication. It methylates cytosine residues at CpG dinucleotides using S-adenosyl-L-methionine (SAM) as the methyl donor, with a 2-fold preference for hemimethylated sites [PMID:18754681]. DNMT1 plays essential roles in genomic imprinting, X-chromosome inactivation, heterochromatin formation, and silencing of repetitive elements.

Core Pathways

DNA Methylation Maintenance Pathway

DNMT1 functions as the primary maintenance methyltransferase during DNA replication, copying methylation patterns from parent to daughter strands. The enzyme recognizes hemimethylated CpG sites created during replication and methylates the unmethylated cytosine on the newly synthesized strand [PMID:8940105]. This process requires coordination with replication machinery and chromatin factors.

UHRF1-Dependent Methylation Pathway

UHRF1 acts as an essential cofactor that recruits DNMT1 to hemimethylated DNA. UHRF1's SRA domain recognizes hemimethylated CpG sites, while its PHD domain binds H3K9me3, linking DNA methylation to histone modifications [PMID:21745816]. USP7 deubiquitinase stabilizes both DNMT1 and UHRF1, forming a regulatory complex at methylated chromatin.

Transcriptional Silencing Pathway

DNMT1-mediated CpG island methylation leads to gene silencing through multiple mechanisms. Methylated DNA recruits methyl-CpG binding proteins (MBDs) which associate with histone deacetylases and chromatin remodeling complexes [PMID:24623306]. This creates a repressive chromatin environment that blocks transcription factor access and RNA polymerase activity.

Pathway Diagram

graph TD A[DNA Replication] --> B[Hemimethylated CpG Sites] B --> C[UHRF1: Recognition Factor] C -->|SRA domain binding| D["DNMT1: Methyltransferase (Nucleus)"] E[SAM: Methyl Donor] --> D D -->|methylation| F[Fully Methylated CpG] E --> G[SAH: Product] H[USP7: Deubiquitinase] -->|stabilizes| D H -->|stabilizes| C I[H3K9me3: Histone Mark] --> C C -->|PHD domain| I F --> J[MBD Proteins: Readers] J --> K[HDACs: Chromatin Modifiers] K --> L[Chromatin Compaction] L --> M[Gene Silencing] N[ZNF304: Recruiter] --> D D --> O[Promoter Hypermethylation] O --> M P[PCNA: Replication Clamp] -.-> D Q[DNMT3A/3B: De novo MTases] <-.->|cooperate| D style D fill:#f9f,stroke:#333,stroke-width:2px style C fill:#ffd,stroke:#333,stroke-width:1px

Upstream Regulators

Downstream Effects

Protein Domains and Functions

Clinical Significance

Cancer

DNMT1 overexpression in cancer leads to:
- Tumor suppressor gene hypermethylation and silencing
- CpG island methylator phenotype (CIMP)
- Therapeutic target for DNA methyltransferase inhibitors (azacitidine, decitabine)

Hereditary Sensory and Autonomic Neuropathy Type 1E

Mutations in DNMT1 cause HSAN1E characterized by:
- Adult-onset sensory neuropathy
- Hearing loss and dementia
- Aberrant DNA methylation patterns

Regulatory Mechanisms

Integration with Epigenetic Networks

DNMT1 coordinates with multiple epigenetic systems:
1. Histone modifications: Links H3K9me3 to DNA methylation via UHRF1
2. Chromatin remodeling: Cooperates with SNF2H and other remodelers
3. De novo methylation: Interacts with DNMT3A/3B for methylation establishment
4. Methyl-CpG readers: Creates binding sites for MBD proteins and MECP2

Cofactor Requirements